Genenta Science S.p.A.

Genenta Science S.p.A. completed the acquisition of the remaining 80.5% equity ownership in A.T.C. S.r.l. for an aggregate purchase price of Euro 9,604,076.82. The payment was made by setting off the amount owed by A.T.C. Shareholders for subscribing to 24,625,838 ordinary shares of Genenta Science at Euro 0.39 per share. The acquired shares are subject to a 36-month lock-up period, and the agreement includes both put and call options for the shares.

Genenta Science S.p.A. announced the termination of its amended and restated license agreement with Ospedale San Raffaele S.r.l. (OSR), effective May 18, 2026. This strategic decision, approved by the Board of Directors, will end the licenses and option rights related to certain technology and intellectual property. The company does not expect to incur any material termination fees or penalties, aside from accrued obligations, and plans to reallocate resources to other strategic initiatives while continuing to support the ongoing glioblastoma multiforme clinical trial.

Genenta Science S.p.A. has entered into a binding consulting agreement with Richard B. Slansky, transitioning him from his employee role as CFO of its US subsidiary, Genenta Science, Inc., to a consultant CFO for the parent company. The agreement, effective April 24, 2026, with services starting June 1, 2026, will run for one year and is non-cancellable, with automatic annual renewals. Mr. Slansky will lead the closure of Genenta Science, Inc., and the company anticipates significant annual savings from this transition.